These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18667303)

  • 21. Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs.
    Zhang P; Bao L; Zuckett JF; Goldman EA; Jia ZJ; Arfsten A; Edwards S; Sinha U; Hutchaleelaha A; Park G; Lambing JL; Hollenbach SJ; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2004 Feb; 14(4):983-7. PubMed ID: 15013006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N,N'-dihydroxyamidines: a new prodrug principle to improve the oral bioavailability of amidines.
    Reeh C; Wundt J; Clement B
    J Med Chem; 2007 Dec; 50(26):6730-4. PubMed ID: 18052320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids.
    Sagi K; Nakagawa T; Yamanashi M; Makino S; Takahashi M; Takayanagi M; Takenaka K; Suzuki N; Oono S; Kataoka N; Ishikawa K; Shima S; Fukuda Y; Kayahara T; Takehana S; Shima Y; Tashiro K; Yamamoto H; Yoshimoto R; Iwata S; Tsuji T; Sakurai K; Shoji M
    J Med Chem; 2003 May; 46(10):1845-57. PubMed ID: 12723948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective and dual action orally active inhibitors of thrombin and factor Xa.
    Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P
    Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
    Gruenewald S; Wahl B; Bittner F; Hungeling H; Kanzow S; Kotthaus J; Schwering U; Mendel RR; Clement B
    J Med Chem; 2008 Dec; 51(24):8173-7. PubMed ID: 19053771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel tetrahydroisoquinoline derivatives as potent and selective factor Xa inhibitors.
    Ueno H; Yokota K; Hoshi J; Yasue K; Hayashi M; Uchida I; Aisaka K; Hase Y; Katoh S; Cho H
    Bioorg Med Chem Lett; 2005 Jan; 15(1):185-9. PubMed ID: 15582437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor.
    Rautio J; Leppänen J; Lehtonen M; Laine K; Koskinen M; Pystynen J; Savolainen J; Sairanen M
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2614-6. PubMed ID: 20231095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
    Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
    J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes).
    Kotthaus J; Steinmetzer T; van de Locht A; Clement B
    J Enzyme Inhib Med Chem; 2011 Feb; 26(1):115-22. PubMed ID: 20583861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives.
    Haginoya N; Kobayashi S; Komoriya S; Hirokawa Y; Furugori T; Nagahara T
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2935-9. PubMed ID: 15125963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase.
    Elworthy TR; Dunn JP; Hogg JH; Lam G; Saito YD; Silva TM; Stefanidis D; Woroniecki W; Zhornisky E; Zhou AS; Klumpp K
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6344-7. PubMed ID: 18993071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of 2-hydroxymethyl-4-[5-(4-methoxyphenyl)-3-trifluoromethyl-pyrazol-1-yl]-N-propionylbenzenesulfonamide sodium as a potential COX-2 inhibitor for oral and parenteral administration.
    Singh SK; Vobbalareddy S; Kalleda SR; Casturi SR; Datla SR; Mamidi RN; Mullangi R; Ramanujam R; Yeleswarapu KR; Iqbal J
    Bioorg Med Chem; 2006 Dec; 14(24):8626-34. PubMed ID: 16949828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.
    Quan ML; Han Q; Fevig JM; Lam PY; Bai S; Knabb RM; Luettgen JM; Wong PC; Wexler RR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1795-8. PubMed ID: 16434195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of potent, selective and orally bioavailable triaryl-sulfonamide based PTP1B inhibitors.
    Patel D; Jain M; Shah SR; Bahekar R; Jadav P; Joharapurkar A; Dhanesha N; Shaikh M; Sairam KV; Kapadnis P
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1111-7. PubMed ID: 22189136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
    Hosaka Y; Matsumoto M; Shinozaki M; Ohno T; Yatagai Y; Kamiya M; Kurokawa M; Nishida H; Matsusue T; Mizuguchi K; Ishii H
    Eur J Pharmacol; 2006 Jan; 529(1-3):164-71. PubMed ID: 16316651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What should be considered on design of a colon-specific prodrug?
    Jung Y; Kim YM
    Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
    Van Huis CA; Bigge CF; Casimiro-Garcia A; Cody WL; Dudley DA; Filipski KJ; Heemstra RJ; Kohrt JT; Narasimhan LS; Schaum RP; Zhang E; Bryant JW; Haarer S; Janiczek N; Leadley RJ; McClanahan T; Thomas Peterson J; Welch KM; Edmunds JJ
    Chem Biol Drug Des; 2007 Jun; 69(6):444-50. PubMed ID: 17581239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.
    Duffy JL; Kirk BA; Wang L; Eiermann GJ; He H; Leiting B; Lyons KA; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 May; 17(10):2879-85. PubMed ID: 17350841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Novel Prodrug of a nNOS Inhibitor with Improved Pharmacokinetic Potential.
    Maccallini C; Marinelli L; Indorf P; Cacciatore I; Fantacuzzi M; Clement B; Di Stefano A; Amoroso R
    ChemMedChem; 2020 Nov; 15(22):2157-2163. PubMed ID: 32783298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.
    Qiao JX; Cheney DL; Alexander RS; Smallwood AM; King SR; He K; Rendina AR; Luettgen JM; Knabb RM; Wexler RR; Lam PY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4118-23. PubMed ID: 18550370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.